NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow ALS progression, announced PrimeC was safe and well tolerated in the interim analysis of study NST002, a Phase IIa study conducted by Principal Investigator Prof. Vivian Drory in Israel at Tel-Aviv Sourasky Medical Center (TASMC). Trends toward slowing of disease progression were seen both in ALSFRS-R and Vital Capacity. These trends were noted in the last 3 months of the 6 month study.
The study, containing 15 patients, is scheduled to continue for an additional 6 months.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"We are very encouraged by the interim results and are now preparing for more analyses that may reveal additional layers of observations. We intend to initiate an additional clinical trial by the beginning of 2021 with the new PrimeC advanced formulation," Alon Ben-Noon, CEO of NeuroSense Therapeutics, said.
"These clinical signals, in conjunction with the very promising preclinical results in multiple ALS models, clearly warrant further investigation in a larger, placebo-controlled study," Jeremy Shefner, MD, PhD, Chair of Neurology at the Barrow Neurological Institute and advisor to the NeuroSense program, said.